Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children

Pieter La Fraaij; Jennifer Neubert; Alina S. Bergshoeff; Annemarie M.C. Van Rossum; Nico G. Hartwig; Horst Schroten; Klaus Korn; David M. Burger; Ronald De Groot; Tim Niehues

Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children

Pieter La Fraaij, Jennifer Neubert, Alina S. Bergshoeff, Annemarie M.C. Van Rossum, Nico G. Hartwig, Horst Schroten, Klaus Korn, David M. Burger, Ronald De Groot, Tim Niehues^*

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › Academic › peer-review

17 Citations (Scopus)

Abstract

We studied a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen for the treatment of children infected with NRTI-resistant HIV-1. The combination of lopinavir/ritonavir and efavirenz suppressed HIV-1 levels for a prolonged period and resulted in a significant increase in CD4+ T cell numbers despite an extensive prior treatment with NRTI (>4 years). Observed side effects were transient with the exception of dyslipidaemia.

Original language	English
Pages (from-to)	297-299
Number of pages	3
Journal	Antiviral Therapy
Volume	9
Issue number	2
Publication status	Published - Apr 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{dde6e967be914eaaaf0ab33804cedbc6,

title = "Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children",

abstract = "We studied a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen for the treatment of children infected with NRTI-resistant HIV-1. The combination of lopinavir/ritonavir and efavirenz suppressed HIV-1 levels for a prolonged period and resulted in a significant increase in CD4+ T cell numbers despite an extensive prior treatment with NRTI (>4 years). Observed side effects were transient with the exception of dyslipidaemia.",

author = "{La Fraaij}, Pieter and Jennifer Neubert and Bergshoeff, {Alina S.} and {Van Rossum}, {Annemarie M.C.} and Hartwig, {Nico G.} and Horst Schroten and Klaus Korn and Burger, {David M.} and {De Groot}, Ronald and Tim Niehues",

year = "2004",

month = apr,

language = "English",

volume = "9",

pages = "297--299",

journal = "Antiviral Therapy",

issn = "1359-6535",

publisher = "SAGE Publications",

number = "2",

}

TY - JOUR

T1 - Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children

AU - La Fraaij, Pieter

AU - Neubert, Jennifer

AU - Bergshoeff, Alina S.

AU - Van Rossum, Annemarie M.C.

AU - Hartwig, Nico G.

AU - Schroten, Horst

AU - Korn, Klaus

AU - Burger, David M.

AU - De Groot, Ronald

AU - Niehues, Tim

PY - 2004/4

Y1 - 2004/4

N2 - We studied a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen for the treatment of children infected with NRTI-resistant HIV-1. The combination of lopinavir/ritonavir and efavirenz suppressed HIV-1 levels for a prolonged period and resulted in a significant increase in CD4+ T cell numbers despite an extensive prior treatment with NRTI (>4 years). Observed side effects were transient with the exception of dyslipidaemia.

AB - We studied a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen for the treatment of children infected with NRTI-resistant HIV-1. The combination of lopinavir/ritonavir and efavirenz suppressed HIV-1 levels for a prolonged period and resulted in a significant increase in CD4+ T cell numbers despite an extensive prior treatment with NRTI (>4 years). Observed side effects were transient with the exception of dyslipidaemia.

UR - http://www.scopus.com/inward/record.url?scp=2342441341&partnerID=8YFLogxK

M3 - Article

C2 - 15134193

AN - SCOPUS:2342441341

SN - 1359-6535

VL - 9

SP - 297

EP - 299

JO - Antiviral Therapy

JF - Antiviral Therapy

IS - 2

ER -

Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this